Table 1.
Demographic and clinical characteristics of the subjects (90 subjects, 168 visits)
| Parameter | Value |
|---|---|
| Age, mean (s.d.), yearsa | 15.4 (3.3) |
| Gender (female), % | 86 |
| Ethnicity (%) | |
| African-American | 11 |
| Asian | 31 |
| Caucasian | 24 |
| Hispanic | 17 |
| Mixed | 17 |
| SLE disease duration, median (range)a, years | 1.6 (0–11.4) |
| SLEDAI, median (range)b | 4 (0–29) |
| SLICC damage index (s.d.)b, units | 0.2 (0.5) |
| Current prednisone dose, median (range)b, mg/kg/day | 0.13 (0–1.9) |
| Use of CYC during lifetime, % | 26.8 |
| Current medications, % | |
| Prednisone | 85.7 |
| HCQ | 84.9 |
| AZA | 1.8 |
| MMF | 1.2 |
| Laboratory parametersb | |
| C3, median (range), mg/dl | 91 (21–196) |
| C4, median (range), mg/dl | 14 (0–46) |
| dsDNA antibody, median (range), IU/ml | 105 (0–6333) |
| ESR, median (range), mm/h | 17 (0–90) |
aAt baseline visit. bAveraged across all visits.